Otoprotective effects of farnesene against oxidative damage induced by paclitaxel

Dinçer, Büşra; Atalay, Fatma; Tatar, Arzu

doi:10.17826/cumj.1093970

Cited by 2 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few clinical trials on the impact of paclitaxel on sensorineural hearing loss have been documented [20,21]. Research revealing the link between hearing loss and paclitaxel, particularly in recent experimental studies, is notable and it is observed that paclitaxel reduces DPOAE frequencies [4,5,22]. Consistent with these results, a decline in DPOAE results was observed in the PCX group in the current research.…”

Section: Discussionsupporting

confidence: 86%

“…In this context, diminishing the excessive ROS generation that underlies the pathophysiology of ototoxicity or boosting the antioxidant system can reduce the ototoxic effect of chemotherapeutics. Exogenous antioxidants are thus the most remarkable agents and have evolved into the main strategy of ototoxicity treatment in research [5,22,[29][30][31].…”

Section: Discussionmentioning

confidence: 99%

“…However, several studies have shown that sesquiterpenes have a protective effect on chemotherapeutics-induced ototoxicity. Farnesene, a natural sesquiterpene, has been reported to exert autoprotective effects in PCX-induced ototoxicity by restoring MDA and GSH levels damaged by oxidative damage [22]. Another sesquiterpene, zingerone has been reported to exert otoprotective effects in cisplatin-induced ototoxicity [29].…”

Section: Discussionmentioning

confidence: 99%

“…Previous research revealed the dose of ZBN [38] (CAS no. 495-60-3, Guide Chem) and PCX [5,22] (Sindaxel; Actavis Drug Co.) to be used. One day after the last drug administration (22. day), the second DPOAE readings were measured.…”

Section: Methodsmentioning

confidence: 99%

“…One day after the last drug administration (22. day), the second DPOAE readings were measured. The drug treatment protocol and PCX-induced ototoxicity model procedures were described in earlier research [5,22].…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Zingiberene attenuates paclitaxel-induced ototoxicity by strengthening cochlear antioxidant defense system in vivo

DINCER¹,

Atalay²,

Tatar³

2023

jrp

View full text Add to dashboard Cite

Paclitaxel is widely used in the treatment of many cancers. Paclitaxel-induced ototoxicity is related to the neurotoxic effects of paclitaxel on auditory peripheral neurons. Zingiberene has significant antitumor and antioxidant properties. This study aimed to determine whether zingiberene protects against the ototoxicity caused by paclitaxel. Twenty-four Wistar Albino rats were divided into four groups. The control group received 1 ml/kg saline on days 1, 7, 14, and 21. The paclitaxel group received 5 mg/kg paclitaxel on days 1, 7, 14, and 21. On days 1, 7, 14, and 21, the zingiberene group received 10mg/kg of zingiberene. Paclitaxel + zingiberene group first 5 mg/kg paclitaxel and 30 minutes later 10mg zingiberene on the 1st, 7th, 14th, and 21st days. A distortion product-evoked otoacoustic emission test (DPOAE) was performed before (day 0) and after (day 22) of the experiment. The pretreatment DPOAE values of the groups were not significantly different. On day 22, the DPOAE results in the paclitaxel group showed a considerable decline. Malondialdehyde levels were substantially higher, and glutathione levels were much lower in the paclitaxel group. The paclitaxel+zingiberene group displayed significantly higher DPOAE levels than the paclitaxel group. Compared to the paclitaxel group paclitaxel+zingiberene, glutathione levels were considerably higher, and malondialdehyde levels were significantly lower. The study findings provide the first evidence in the literature that zingiberene can prevent ototoxicity from paclitaxel-induced hearing loss by lowering the levels of oxidant parameters. It demonstrates that administering zingiberene and paclitaxel together may be a practical clinical approach to alleviate paclitaxelinduced ototoxicity.

show abstract